Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 15.50 22,715 08:00:00
Bid Price Offer Price High Price Low Price Open Price
15.00 16.00 15.50 15.50 15.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 78.20 8.07 1.11 14.0 100
Last Trade Time Trade Type Trade Size Trade Price Currency
14:48:38 O 950 15.70 GBX

Allergy Therapeutics (AGY) Latest News

More Allergy Therapeutics News
Allergy Therapeutics Takeover Rumours

Allergy Therapeutics (AGY) Discussions and Chat

Allergy Therapeutics Forums and Chat

Date Time Title Posts
28/9/202016:51Allergy Therapeutics - AGY -3,905
14/7/201621:04Mike Mitchell Panmure Gordon who covers Allergy Therapeutics PLC (LON:AGY)1
16/12/201510:24Allergy Therapeutics-Transforming Allergy Treatment26
03/2/201213:58Ready to ROCKET?-
04/12/200512:00AGY - Allergy Therapeutics79

Add a New Thread

Allergy Therapeutics (AGY) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-09-29 13:48:3915.70950149.15O
2020-09-29 08:54:0615.0015,3652,304.75O
2020-09-29 08:40:0015.701,400219.80O
2020-09-29 07:55:3015.705,000785.00O
View all Allergy Therapeutics trades in real-time

Allergy Therapeutics (AGY) Top Chat Posts

DateSubject
29/9/2020
09:20
Allergy Therapeutics Daily Update: Allergy Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AGY. The last closing price for Allergy Therapeutics was 15.50p.
Allergy Therapeutics Plc has a 4 week average price of 15.50p and a 12 week average price of 10.95p.
The 1 year high share price is 21.75p while the 1 year low share price is currently 7.38p.
There are currently 644,117,768 shares in issue and the average daily traded volume is 380,114 shares. The market capitalisation of Allergy Therapeutics Plc is £99,838,254.04.
28/9/2020
16:51
a1samu: A share fluctuates so much because of infrequent good news, mistrust of the management and mindless management of the share price! If shares were controlled and any surplus absorbed, MM would have no chance to mess it about, which they do to their own hearts delight with this one! Besides nobody wants this share because of lack of any inspiration or vision of the future, so this just drifts and drifts as it will continue to do so. The price went up to over 20p in anticipation of the recent announcement, why should it drift so seriously if there was such a convincing story to tell? It should continue upwards if the market believed the story of the management.
28/9/2020
11:07
a1samu: What matters is what the market sys through the share price and the market says this is rubbish! And on top nobody wants this share!
02/9/2020
10:13
jimmyloser: impo, nothing has kicked the share price off. We have nickel and dime trading right now (wait until results day, 23rd) This was a rock solid 25p+ share until the setback, other than trials which are always risky for shareholders, these guys deliver. They now have a bigger bag of tricks to play with and we should see them back solidly in the 20's by the end of this month. Always risky being in medicinal's impo/dyor but it can be very rewarding
29/8/2020
08:02
a1samu: Some reasons why the share price is improving! Allergy Therapeutics PLC 15 July 2020 Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group") Trading Update - Strong 2020 performance despite COVID-19 challenge - Earnings above market expectations - Net revenue of GBP78.2million representing 6% annual growth - Strong cash balance of GBP37.0 million - Phase I Peanut program fully funded from existing resources - Licencing deal signed for new oral treatment, ImmunoBON - COVID-19 diagnostic facility approved by Spanish authorities 15 July 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provides a trading update for the year ended 30 June 2020 ahead of its Preliminary Results to be announced on 23 September 2020. Financials The Group now expects earnings for the full year 2020 to be ahead of market expectations as announced on 24 June 2020. Net revenue is expected to be GBP78.2million (2019: GBP73.7million) representing 6% annual growth (7% growth on a constant currency basis) reflective of a very robust performance in challenging circumstances. Operating efficiencies and timing of the research and development spend have led to strong overall performance with the Group likely to report a significant, positive net income for the year. Due to the Group's strong performance, the Executive Management has taken the decision to repay all UK furlough monies claimed back to the government. The cash balance at 30 June 2020 was GBP37.0 million (30 June 2019: GBP27.4 million). The Group's total bank loan debt was GBP3.8 million (30 June 2019: GBP2.4 million). Based on current assumptions, the Group expects to be able to fully fund the upcoming Grass MATA MPL pilot and pivotal Phase III field studies and the Phase I Peanut programme with existing cash resources and a small amount of additional debt. Response to COVID-19 and Commercial Update The Group has coped well with the challenge presented by COVID-19. After an initial decline, sales improved and have only been moderately affected due to patients not visiting clinics and hospitals. Trading in Southern Europe has been more heavily impacted than in Northern Europe, owing to the greater number of allergy clinics located within hospitals in Southern Europe. The sales and marketing team across Europe has responded rapidly to provide broad support to doctors, hospitals and patients. Encouragingly, the easing of restrictions is reflected in the final month of the year, with sales returning to previous levels. From the beginning of the COVID-19 outbreak, the Group has taken steps to ensure the safety of its employees. This was achieved, in part, by implementing social distancing measures within the Group's operations and splitting vital functions into separate teams to minimise the risk of workers becoming ill and slowing production and transport across the continent. Throughout the COVID-19 situation, the Group has maintained a constant supply of its products across all markets with no disruption in the supply chain. All areas of the business have reacted well to the challenges of COVID-19, with approximately two-thirds of staff working remotely. Clear communication with internal and external stakeholders and a strong collaborative approach in line with the Group's values and behaviours, have helped to ensure minimum disruption. COVID -19 Diagnostic Facility In response to the urgent need to increase the global capacity to diagnose infected COVID-19 patients, the Group has invested capital into expanding its microbiological diagnostic facilities in Spain, by incorporating an RT-PCR based SARS-COV-2 diagnostic test into its portfolio. The RT-PCR technique can detect a fragment of RNA (the genetic material) derived from the SARS-COV-2 virus to determine if the patient is currently infected. The Group's expanded microbiology facilities in Alcalá, named AT Immunolab, have been authorised by Spanish Health Authorities and will provide support in this healthcare crisis helping healthcare providers and patients in this difficult situation. The project has been set up in a significantly accelerated timeframe and received financing from the Centre for the Development of Industrial Technology and the Technology Fund, from the Ministry of Science, Innovation and Universities of Spain. AT Immunolab began SARS-COV-2 testing in the first week of July and, at full capacity, is expected be able to perform 200,000 tests a year. Pipeline Previously communicated R&D plans continue to be executed and the Grass MATA MPL clinical programme is expected to start next month as planned, with the pilot field study in about 150 adults to be recruited in the US and Europe. The study will implement COVID-19 related procedures, flexibility and strategies to minimise the impact of COVID-19. Limited impact on clinical operations or regulatory activities is expected. The Group has signed a knowledge-sharing agreement with Saiba AG, owners of the virus-like particle (VLP) platform currently licensed to Allergy Therapeutics for allergy indications, to assist with the development of Saiba's COVID-19 vaccine candidates. The agreement has the potential to benefit the Group in the future, by supplying pre-clinical and clinical data using the same novel VLP platform to support the Group's peanut vaccine candidate programme. The Group has also signed a commercial agreement with Biomedical International R+D GmbH for the exclusive rights to ImmunoBON, a patented protein-based oral treatment which was developed to replicate the reduction in incidence of allergy as seen by those who live on a farm with livestock, the so-called "farm effect". In a preclinical study programme, the immunogenicity of the protein formulation with the selected ligands was proven, as well as the capacity to prevent allergic sensitisation(1-5) . At the scientific congress of the European Academy of Allergy and Clinical Immunology in June 2020, two poster presentations demonstrated that the product significantly reduced allergic symptoms in a mouse model(6) , and also among patients in a double-blind placebo controlled pilot study(7) when compared to placebo treatment. Additionally, a recently completed study in an allergen exposure chamber (European Centre for Allergy Research Foundation, Berlin, Germany) revealed significant improvement in allergy symptoms in house dust mite allergic patients (data on file).The product will initially be available in Germany with roll out across the rest of Europe to follow. Manuel Llobet, CEO at Allergy Therapeutics , stated: "Our focus during the COVID-19 pandemic has been the safety and well-being of all of our employees, partners and customers and I am proud of our robust and rapid response to the challenges presented during this time. When the outbreak started in Europe, we made a commitment as a group to leverage our strengths. Our business has put in place new efficiencies, highlighting our resilience and agility in times of change and we are thriving as a result. Our plans to develop a strong R&D pipeline remains on track and our two recently signed agreements with partners provides exciting new opportunities for our VLP technology and our oral treatment offerings for allergy patients. I am especially proud of our team and would like to thank them for their unwavering commitment and desire to drive the business forward." This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014. -S - For further information, please contact: Allergy Therapeutics +44 (0) 1903 845 820 Manuel Llobet, Chief Executive Officer Nick Wykeman, Chief Financial Officer Panmure Gordon +44 (0) 20 7886 2500 Freddy Crossley, Emma Earl, Corporate Finance James Stearns, Corporate Broking Consilium Strategic Communications +44 20 3709 5700 Mary-Jane Elliott / David Daley / Ashley Tapp / Olivia Manser allergytherapeutics@consilium-comms.com Stern Investor Relations, Inc. +1 212 362 1200 Christina Tartaglia christina@sternir.com
28/8/2020
08:42
jimmyloser: This is indeed good to see, I guess it was a case of the share price being over hammered. The management did what they had to in cases like this and just got on with making sure that the business delivered. They and we have been through a very tough time, but patience and belief will be and is being rewarded. Considering the box of tricks that they have up their sleeves, this lowly share price remains a mystery to me.............but for how long? (Yes, I have been buying solidly) dyor/impo
15/7/2020
14:23
hedgehog 100: 15/07/2020 07:00 UKREG Allergy Therapeutics PLC Trading Update "Trading Update - Strong 2020 performance despite COVID-19 challenge - Earnings above market expectations - Net revenue of GBP78.2million representing 6% annual growth - Strong cash balance of GBP37.0 million - Phase I Peanut program fully funded from existing resources - Licencing deal signed for new oral treatment, ImmunoBON - COVID-19 diagnostic facility approved by Spanish authorities 15 July 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provides a trading update for the year ended 30 June 2020 ahead of its Preliminary Results to be announced on 23 September 2020. ... COVID -19 Diagnostic Facility In response to the urgent need to increase the global capacity to diagnose infected COVID-19 patients, the Group has invested capital into expanding its microbiological diagnostic facilities in Spain, by incorporating an RT-PCR based SARS-COV-2 diagnostic test into its portfolio. The RT-PCR technique can detect a fragment of RNA (the genetic material) derived from the SARS-COV-2 virus to determine if the patient is currently infected. The Group's expanded microbiology facilities in Alcalá, named AT Immunolab, have been authorised by Spanish Health Authorities and will provide support in this healthcare crisis helping healthcare providers and patients in this difficult situation. The project has been set up in a significantly accelerated timeframe and received financing from the Centre for the Development of Industrial Technology and the Technology Fund, from the Ministry of Science, Innovation and Universities of Spain. AT Immunolab began SARS-COV-2 testing in the first week of July and, at full capacity, is expected be able to perform 200,000 tests a year. ..." https://uk.advfn.com/stock-market/london/allergy-therapeutics-AGY/share-news/Allergy-Therapeutics-PLC-Trading-Update/82855583
14/7/2020
17:21
hedgehog 100: 09/07/2020 07:00 UKREG Allergy Therapeutics PLC Invalidation of Birch MATA MPL phase III results " ... "We look forward to progressing our portfolio of unique allergy vaccines and helping the millions of patients affected by allergy via our phase III studies with Birch MATA MPL as well as Grass MATA MPL and our upcoming first in human peanut trial." ..." https://uk.advfn.com/stock-market/london/allergy-therapeutics-AGY/share-news/Allergy-Therapeutics-PLC-Invalidation-of-Birch-MAT/82821177 jimmyloser 9 Jul '20 - 15:57 - 3849 of 3849 0 2 0 "To-days very encouraging news release which was totally misread by the market should draw a line under lingering doubts on he Mata programme. Certainly one analysts note thinks so and keeps the target price of 40p with dust mite and peanut not being valued!!! But dyor" Thank for that analyst snippet Jimmy. AGY has traded above £1 a share in the past, and after a challenging period it looks to be heading back in that direction.
24/6/2020
15:00
hedgehog 100: AGY's next financial year, i.e. July 2020 - June 2021, starts in just a week, and will see several important clinical trials: 04/03/2020 07:00 UK Regulatory (RNS & others) Allergy Therapeutics PLC Half-year Report " ... Outlook This calendar year is key in order to prepare for several important trials for the 2021 financial year. ..." https://uk.advfn.com/stock-market/london/allergy-therapeutics-AGY/share-news/Allergy-Therapeutics-PLC-Half-year-Report/81906114 But unlike most biotechs, AGY's strong cash position and trading gives it very solid value underpinning, meaning that the potential huge upside from trials success is 'in for free'. With a big bonus being potential involvement in COVID-19 vaccines. And I would expect an RNS on that last point soon. Indeed I believe that today's trading update 'paves the way' for a COVID-19 RNS. Similar to ODX in April, where a trading upate was followed a week later by a COVID-19 RNS. And during April the ODX share price multibagged. 02/04/2020 07:00 UK Regulatory (RNS & others) Omega Diagnostics Group PLC Trading Update 09/04/2020 07:00 UK Regulatory (RNS & others) Omega Diagnostics Group PLC COVID-19 Consortium MOU
24/6/2020
14:15
hedgehog 100: Short and sweet - the facts speak for themselves. Jimmyloser - at this rate, you may have to change your name! 24/06/2020 07:00 UKREG Allergy Therapeutics PLC Trading Update "2020 performance to exceed market expectations 24 June 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today provides a trading update for the year ended 30 June 2020. Reported revenues for the year ended 30 June 2020 are expected to be at least 4% ahead of last year in constant currency terms. A programme of operating cost efficiencies, together with the timing of the planned research and development expenditure over the 3 years to June 2022, are expected to deliver a net profit for the year significantly above market expectations. The Board looks forward to providing a further update to shareholders for the year to 30 June 2020 in the week commencing 13 July 2020. This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014." https://uk.advfn.com/stock-market/london/allergy-therapeutics-AGY/share-news/Allergy-Therapeutics-PLC-Trading-Update/82716488
23/5/2020
19:50
hedgehog 100: Allergy Therapeutics (11.25p) is a potential play on COVID-19 vaccines in two ways: 1. VACCINE MANUFACTURING CAPACITY. 04/03/2020 07:00 UK Regulatory (RNS & others) Allergy Therapeutics PLC Half-year Report " ... About Allergy Therapeutics Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com . ..." https://uk.advfn.com/stock-market/london/allergy-therapeutics-AGY/share-news/Allergy-Therapeutics-PLC-Half-year-Report/81906114 2. VACCINE ADJUVANT TECHNOLOGIES. AGY's website specifically mentions infectious diseases in this respect. (Infectious diseases include those caused by viruses, e.g. coronavirus, and vaccine adjuvant technologies could improve the efficacy of COVID-19 vaccines.) "About adjuvant systems Our adjuvant technologies not only advance the results of allergy immunotherapy but also drive beneficial immune responses in cancer and infectious disease. They improve therapies by allowing them to act faster and we now help others by using this knowledge; improving health and developing vaccinations for infectious disease and cancer treatments. Through our Bencard Adjuvant Systems division we are engaging in long-term partnerships with those who require our patented platform of adjuvant technologies to enable successful vaccine or immunotherapy development." HTTP://www.allergytherapeutics.com/our-science/specialist-expertise/ 22/04/2020 10:11 RNSNON Allergy Therapeutics PLC EAACI review of adjuvants and formulations " ... Adjuvant technology, which has the potential to create immunotherapies that act faster and work more efficiently than traditional therapies, is a key element of Allergy Therapeutics' strategy to research and develop innovative allergy immunotherapies. Through its Bencard Adjuvant Systems division, the Group also engages in long-term partnerships with those requiring its patented platform of adjuvant technologies to enable successful vaccine or immunotherapy development in areas outside allergy. ... Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: "We have developed biodegradable adjuvants that make allergy treatment more efficient than ever - a key technology in our pioneering approach to the development of innovative treatments for allergy patients. This paper endorses the approach we have taken at Allergy Therapeutics, through our important and growing Bencard Adjuvant Systems division, to invest in innovative adjuvant technology that aim to make our therapies as convenient as they are effective([1]) and to improve future vaccines in other disease indications in areas such as influenza, cancers and malaria([2-5]) ." ..." https://uk.advfn.com/stock-market/london/allergy-therapeutics-AGY/share-news/Allergy-Therapeutics-PLC-EAACI-review-of-adjuvants/82279979
Allergy Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
AGY
Allergy Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200930 01:02:52